Harvard Medical School, Boston, MA, USA.
Beth Israel Deaconess Medical Center, Boston, MA, USA.
Leuk Lymphoma. 2023 May;64(5):972-980. doi: 10.1080/10428194.2023.2185091. Epub 2023 Mar 24.
Myeloid sarcoma (MS) is currently considered equivalent to de novo acute myeloid leukemia (AML); however, the relationship between these entities is poorly understood. This retrospective multi-institutional cohort study compared 43 MS with mutation to 106 AML with mutation. Compared to AML, MS had more frequent cytogenetic abnormalities including complex karyotype ( = .009 and = .007, respectively) and was enriched in mutations of genes involved in histone modification, including ( = .007 and = .008, respectively). AML harbored a higher average number of gene mutations ( = .002) including more frequent mutations ( < .001) and mutations of DNA-methylating genes including and (both < .001). MS had significantly shorter overall survival (OS) than AML (median OS: 44.9 vs. 93.2 months, respectively, = .037). MS with mutation has a unique genetic landscape, and poorer OS, compared to AML with mutation.
骨髓肉瘤 (MS) 目前被认为等同于初发急性髓细胞性白血病 (AML)；然而，这两种实体之间的关系尚不清楚。本回顾性多机构队列研究比较了 43 例 突变的 MS 和 106 例 突变的 AML。与 AML 相比，MS 更常出现细胞遗传学异常，包括复杂核型（分别为 =.009 和 =.007），并且富含组蛋白修饰相关基因突变，包括 （分别为 =.007 和 =.008）。AML 平均携带更多基因突变（ =.002），包括更常见的 突变（ <.001）和 DNA 甲基化基因的突变，包括 和 （均为 <.001）。MS 的总生存期 (OS) 明显短于 AML（中位 OS：44.9 与 93.2 个月，分别为 =.037）。与 AML 相比，MS 具有独特的遗传特征，并且 OS 更差。
